Provided is the use of an anti-CD4 antibody or antigen binding fragment thereof and a psoralen in the manufacture of a medicament for the treatment of a CD4+ T-cell mediated condition selected from the group consisting of primary cancer, metastatic cancer and inflammatory skin disease in a subject, and wherein the anti-CD4 antibody is zanolimumab or an anti-CD4 antibody or antigen binding fragment thereof comprising all six CDR sequences of the antibody zanolimumab.
